Which vaccine could effectively reduce the incidence of shingles in adults?

Zostavax is a vaccine specifically designed to reduce the incidence of shingles, also known as herpes zoster, in adults. It is recommended primarily for older adults, typically those aged 50 years and older, because the risk of developing shingles increases with age. This vaccine works by boosting the immune response to the varicella-zoster virus, which remains in the body after a person has had chickenpox. By enhancing immunity, Zostavax decreases the likelihood of reactivation of the virus, which is what causes shingles.

In contrast, Varivax is a vaccine intended for the prevention of chickenpox itself, not shingles. The HPV vaccine targets human papillomavirus and is unrelated to shingles prevention, while the Tdap vaccine is aimed at preventing tetanus, diphtheria, and pertussis. Therefore, Zostavax is the most appropriate choice for reducing shingles incidence among adults.